v3.26.1
Segment Information
 6 Months Ended
Jun. 30, 2026
Segment Information [Abstract]  
SEGMENT INFORMATION

NOTE 13. SEGMENT INFORMATION

 

The Company has determined it operates as a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma. The Company’s chief operating decision maker, its Chief Executive Officer (the “CEO”), manages the Company’s operations on a consolidated basis. The CEO assesses the segment’s performance and allocates resources based on review of various development, manufacturing and clinical programs expenses, along with the segment’s personnel and general and overhead costs.

 

In addition to the significant expense categories included within net loss presented in the Company’s condensed consolidated statements of operations and comprehensive loss, see below for disaggregated amounts that comprise total operating expenses (in thousands):

 

    Three Months Ended
June 30,		     Six Months Ended
June 30,		  
    2026     2025     2026     2025  
Personnel-related costs   $ 2,174     $ 7,175     $ 6,212     $ 15,606  
General and overhead costs     3,449       4,132       6,740       7,743  
                                 
Program costs                                
Briquilimab platform     300       1,878       566       3,835  
CMO     943       6,513       1,825       8,651  
CSU     2,047       4,094       4,425       6,840  
Asthma     41       1,926       (286 )     3,319  
CIndU     253       828       677       1,713  
SCID     —       368       —       891  
MDS/AML     —       162       —       280  
Total program costs     3,584       15,769       7,207       25,529  
Total operating expense     9,207       27,076       20,159       48,878  
Other income, net     6,447       353       16,225       914  
Net loss   $ (2,760 )   $ (26,723 )   $ (3,934 )   $ (47,964 )

 

All long-lived assets are located in the United States.